

Curriculum Vitae

Personal information Régis Costello

Work experience

2000 Senior Lecturer - Hospital Practitioner
2004- Professor of Universities - Hospital Practitioner in Hematology
2005- Head of Hematology and Cellular Therapy Department, CHU La Conception, Marseille
2007 Specialized Master in Medical Management, (Ecole Supérieure de Commerce, Paris).
2010- Hematology Team, TAGC/INSERM U1090, Luminy, Marseille.

Education and training

1981 Faculty of Medicine of Marseille
1988 Certificate of Immunology Faculty of Sciences of Luminy
1989 Master in Immunology INSERM U119 / Faculty of Sciences
1993 Postgraduate Thesis in Immunology, Faculty of Sciences of Luminy.
1994 Thesis of Medicine, Faculty of Medicine of Marseille.
1996 Validation Internal Medicine & Hematology

Additional information

Publications

Publications last 5 years:

Data from ResearchGate December 2024;

• Items ;	278 (263 articles)
• Reads ;	17515
• Citations ;	5107
• h-index ;	39
• Research Interest Score ;	2495

2020

- 128) Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, **Costello R**, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B. [lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.](#) Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8. PMID: 31702836
- 129) Rebolledo-Rios R, Venton G, Sánchez-Redondo S, Iglesias I, Felip C, Fournet G, González E, Romero Fernández W, Borroto Escuela DO, Di Stefano B, Penarroche-Díaz R, Martin G, Ceylan I, **Costello R**, Perez-Alea M. Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer. Oncogene. 2020 Mar;39(13):2756-2771. doi: 10.1038/s41388-020-1184-9. Epub 2020 Feb 3. PMID: 32015486
- 130) Couderc AL, Puchades E, Villani P, Arcani R, Farnault L, Daumas A, Courcier A, Greillier L, Barlesi F, Duffaud F, Salas S, **Costello R**, Gentile G, Pradel V, Suchon P, Venton G. High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer. Oncologist. 2020 Dec;25(12):e1980-e1989. doi: 10.1634/theoncologist.2019-0894. Epub 2020 Aug 19. PMID: 32745312
- 131) Besson C, Noel N, Lancar R, Prevot S, Algarte-Genin M, Rosenthal E, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Cheret A, Arvieux C, Katlama C, Salmon D, Boué F, **Costello R**, Hendel-Chavez H, Taoufik Y, Fontaine H, Coppo P, Mounier N, Delobel P, Costagliola D; Lymphovir and FHDH study groups. Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. AIDS. 2020 Mar 15;34(4):599-608. doi: 10.1097/QAD.0000000000002461. PMID: 31833850
- 132) Ivanov V, Farnault L, Mercier C, Colavolpe C, Venton G, Colle J, Lepidi H, Arnoux I, Nicolino-Brunet C, Berda-Haddad Y, Fanciullino R, Ivanov G, **Costello R**. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2020 May;61(5):1230-1233. doi: 10.1080/10428194.2019.1706737. Epub 2020 Jan 3. PMID: 31900013
- 133) Roché P, Venton G, Berda-Haddad Y, Fritz S, Ivanov V, Mercier C, Colle J, Tichadou A, Fanciullino R, Lepidi H, **Costello R**, Farnault L. [Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?](#)

2021

134) Donnette M, Ciccolini J, Pissier C, **Costello R**, Duffaud F, Salas S, Farnault L, Tichadou A, Arcani R, Jarrot PA, Ouafik LH, Venton G, Fanciullino R. HIGH INCIDENCE OF CDA DEFICIENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: PERSPECTIVES AND THERAPEUTIC IMPLICATIONS. Ann Oncol. 2021 Jan 30:S0923-7534(21)00100-9. doi: 10.1016/j.annonc.2021.01.072. Online ahead of print. PMID: 33529741.

135) Velier M, Priet S, Appay R, Atieh T, Lepidi H, Kaplanski G, Jarrot PA, Koubi M, **Costello R**, Dignat-George F, de Lamballerie X, Tichadou A, Arcani R, Couderc AL, Touati J, Varoquaux A, Berda-Haddad Y, Venton G. Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2021 Jan 13:S2152-2650(21)00006-9. doi: 10.1016/j.clml.2021.01.005. Online ahead of print. PMID: 33563581

136) Couderc AL, Suchon P, Saliba-Serre B, Rey D, Nouguerede E, Arcani R, Farnault L, Daumas A, Courcier A, Duffaud F, Salas S, Barlesi F, Greillier L, **Costello R**, Venton G, Villani P. [Functional status in older patients with cancer.](#) J Geriatr Oncol. 2021 Jul 27:S1879-4068(21)00165-X. doi: 10.1016/j.jgo.2021.07.004.

137) Madaci L, Colle J, Venton G, Farnault L, Liorid B, **Costello R**. [The contribution of single-cell analysis of acute leukemia in the therapeutic strategy.](#) Biomark Res. 2021 Jun 27;9(1):50. doi: 10.1186/s40364-021-00300-0.

138) Donnette M, Hamimed M, Ciccolini J, Berda-Haddad Y, Kaspi E, Venton G, Lacarelle B, **Costello R**, Ouafik L, Farnault L, Fanciullino R. [Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.](#) J Control Release. 2021 Aug 18;338:244-252. doi: 10.1016/j.jconrel.2021.08.023.

139) Arcani R, Colle J, Cauchois R, Koubi M, Jarrot PA, Jean R, Boyer A, Lachamp J, Tichadou A, Couderc AL, Farnault L, **Costello R**, Venton G, Kaplanski G. [Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.](#) Ann Hematol. 2021 Sep 13:1-5. doi: 10.1007/s00277-021-04656.

2022

140) Joshua Brody MD, Björn E. Wahlin MD, PhD, Tycel Phillips MD, **Régis Costello** MD, PhD, Pieterella Lugtenburg MD, PhD, Raul Cordoba MD, PhD, Liwei Wang PhD, Jun Wu MD, MS, Brian Elliott MD, Aqeel Abbas MS, Judit Jørgensen MD, PhD. Subcutaneous Epcoritamab With Gemcitabine + Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT). October 2022 [Clinical Lymphoma, Myeloma and Leukemia](#) 22:S379-S380 DOI: [10.1016/S2152-2650\(22\)01541-5](#)

141) Norman Abbou, Pauline Piazzola, Jean Gabert, Vincent Ernest, Robin Arcani, Anne-Laure Couderc, Antoine Tichadou, Pauline Roche, Laure Farnault, Julien Colle, L'houcine Ouafik, Pierre Morange, **Régis Costello** and Geoffroy Venton. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm. December 2022 [Cells](#) 12(1):105 DOI:[10.3390/cells12010105](#)

142) Frankel D, Kaspi E, Grosdidier C, Arpin M, Costello R, Roll P. Enigma portal: Peritoneal effusion in a patient with a myeloproliferative neoplasm. Cytopathology. 2023 Jan;34(1):84-86. doi: 10.1111/cyt.13186. Epub 2022 Nov 4. PMID: 36226841.

2023

143) Combaluzier S, Quessada J, Abbou N, Arcani R, Tichadou A, Gabert J, **Costello R**, Loosveld M, Venton G, Berda-Haddad Y. Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells. 2023 Mar 20;12(6):946. doi: 10.3390/cells12060946. PMID: 36980287; PMCID: PMC10047531.

144) Donnette M, Osanno L, Giocanti M, Venton G, Farnault L, Berda-Haddad Y, **Costello R**, Caroline S, Ouafik L, Ciccolini J, Fanciullino R. Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients. Cancer Chemother Pharmacol. 2023 Mar;91(3):231-238. doi: 10.1007/s00280-023-04505-y. Epub 2023 Mar 1. PMID: 36859512.

145) Madaci L, Farnault L, Abbou N, Gabert J, Venton G, **Costello R**. Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia/Myelodysplastic Neoplasms. Cancers (Basel). 2023 Jun 22;15(13):3280. doi: 10.3390/cancers15133280.

146) Madaci L, Gard C, Nin S, Venton G, Rihet P, Puthier D, Liorid B, Costello R. The Contribution of Multiplexing Single Cell RNA Sequencing in Acute Myeloid Leukemia. Diseases. 2023 Jul 12;11(3):96. doi: 10.3390/diseases11030096.

147) Berton G, Arcani R, Tichadou A, Farnault L, Roche P, Colle J, Ivanov V, Mercier C, Couderc AL, **Costello R**, Taïeb D, Venton G. Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy. Leuk Lymphoma. 2023 Jul-Aug;64(7):1355-1357. doi: 10.1080/10428194.2023.2199896. Epub 2023 Apr 12. PMID: 37042674.

148) Fornecker L, Delwail V, Thieblemont C, Ghesquieres H, Bouabdallah K, Tilly H, Le Calloch R, Morschauser F, **Costello R**, Slama B, Gyan E, Chauchet A, Ngirabacu M, Durot E, Choquet S, Capdupuy C, Le Goff M, Voillat L, Snauwaert S, Amorim S. Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non-Hodgkin lymphoma. Results from a phase II LYSA study (PIVER). June 2023 Hematological Oncology 41(S2):437-437, DOI: 10.1002/hon.3164_322

149) Opat S, Tedeschi A, Hu B, Linton K, Mckay P, Leitch S, Jin Jie, Sun M, Sobieraj-Teague M, Luigi Z, Pier, Browett Peter, Thieblemont C, Liberati M A, Bachy E, Cavallo F, **Costello R**, Iyengar S, Marasca R, Mociková H, Seok K, JJ, Talaulikar D, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. P1084: LONG-TERM EFFICACY AND SAFETY

OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL. August 2023HemaSphere 7(S3):e77003b0. DOI: 10.1097/01.HS9.0000971232.77003.b0

150) Courta J, Balzano M, Passe-Coutrin W, Lagier M, Grivel K, Boulay Moine D, Beroual D, Bauchet A-L, Venton G, **Costello R**, Moulard M. Stability Assessment of Fresh or Cryopreserved Whole Blood and Bone Marrow Samples from AML and B-ALL Patients to Monitor CD123 Receptor and Immune Cells Subsets November 2023. [Blood](#) 142(Supplement 1):6032-6032. DOI: [10.1182/blood-2023-179207](#).

151) Brody J, Mészáros Joergensen J, Belada D, **Costello R**, Trněný M, Vitolo U, Lewis D, Karimi Y H, Sureda Balari A M, André M, Wahlin B E, Lugtenburg P, Galderisi F, Abbas A,

Song Y, Risum M, Cordoba R. Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2. November 2023Blood 142(Supplement 1):3092-3092. DOI: 10.1182/blood-2023-180246

152) Prades S, Los S-L, Saïas-Magnan J, Bujan L, Eustache F, Blagosklonov O, Lechevallier E, Brugnol F, Loup-Cabaniols V, Bosquet D, Prades M, Ducrocq B, Chalas S, Giscard-d'Estaing S, Mayeur A, Koscinsky I, Schmitt F, Papaxanthos-Roche A, Teletin M, Thibault E, Beauvillard D, Mirallie S, Delepine B, Benhaim A, May-Panloup P, Veau S, Frapsauce C, Fauque P, **Costello R** and the CECOS network. Efficient pathway for men fertility preservation in testicular cancer or lymphoma: a cross-sectional study of national 2018 data. Basic and Clinical Andrology volume 33, Article number: 35 (2023).

153) Madaci L, Gard C, Nin S, Sarabay A, Baier C, Venton G, Rihet P, Puthier D, Loriod B, **Costello R**. Single-Cell Transcriptome Analysis of Acute Myeloid Leukemia Cells Using Methanol Fixation and Cryopreservation. *Diseases* **2024**, 12, 1. <https://doi.org/10.3390/diseases12010001>.

2024

154) Brody J, Jørgensen J, Belada D, **Costello R**, Trněný M, Vitolo U, Lewis D J, Karimi Y, Sureda A, André M, Wahlin B E, Lugtenburg P J, Galderisi F C, Abbas A, Song Y, Risum M, Cordoba R, Risum S. High Complete Metabolic Response Rates with Epcoritamab SC + GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2. Transplantation and Cellular Therapy, Volume 30, Issue 2, Supplement, 2024, Page S357, ISSN 2666-6367, <https://doi.org/10.1016/j.jtct.2023.12.499>.

155) Rafii H, Volt F, Bierings M, Dalle J H, Ayas M, Rihani R, Faraci M, de Simone G, Sengelojev H, Passweg J, Cavazzana M, **Costello R**, Maertens J, Biffi A, Johansson J E, Montoro J, Roth-Guepin G, Diaz M A, Sirvent A, Kenzey C, Rivera Franco m M, Cappelli B, Scigliuolo G M, Rocha V, Ruggeri A, Risitano A, Peffault De Latour R, Gluckman E. Umbilical Cord Blood Transplantation for Fanconi Anemia With a Special Focus on Late Complications: a Study on Behalf of Eurocord and SAAWP-EBMT. Transplantation and Cellular Therapy, Volume 30, Issue 5, 2024, Pages 532.e1-532.e16, ISSN 2666-6367, <https://doi.org/10.1016/j.jtct.2024.02.024>.

156) Pardee T S, Powell B L, Larson r A, Maly J, Keng M, Foster M, Choi E-J, Sill H, Cluzeau T, Jeyakumar D, Frankfurt O, Patel P, Schuster M, Koller E, **Costello R**, Platzbecker U, Montesinos P, Vives S, Nazha A, Cook R, Vigil-Gonzales C, Chantepie S, Luther S, Cortes J. Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial. Blood Neoplasia, Volume 1, Issue 2, 2024, 100009, ISSN 2950-3280, <https://doi.org/10.1016/j.bneo.2024.100009>.

157) Brody j D, Meszaros Joergensen J, Belada D, **Costello R**, Trneny M, Vitolo U, Lewis D J, Karimi Y, Sureda A, Andre M, Wahlin B E, Lugtenburg P, Jiang Y, Abbas A, Song Y, Risum M, Cordoba R. Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2. Journal of Clinical Oncology. Volume 42, Number 16_suppl. https://doi.org/10.1200/JCO.2024.42.16_suppl.7037.

158) Maroselli P, Fanciullino R, Colle J, Farnault L, Roché P, Venton G, **Costello R**, Ciccolini J. Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy. Journal of Clinical Oncology. Volume 42, Number 16_suppl. https://doi.org/10.1200/JCO.2024.42.16_suppl.e18522

159) Bestion E, **Costello R**, Mezouar S, Halfon P. Autophagy in cancer resistance: New combinatorial strategy for cancer therapy. Leukemia. 2024 Oct;38(10):2289-2290. doi: 10.1038/s41375-024-02342-3.

160) Venton G, Colle J, Tichadou A, Quessada J, Baier C, Labiad Y, Perez M, De Lassus L, Loosveld M, Arnoux I, Abbou N, Ceylan I, Martin G, **Costello R**. Reactive oxygen species and aldehyde dehydrogenase 1A as prognosis and theragnostic biomarker in acute myeloid leukaemia patients. Cell Mol Med. 2024 Oct;28(19):e70011. doi: 10.1111/jcmm.70011.

Projects

Research interests/skills

Main: Immunology/Natural Killer cells, Immune escape/ Acute Myeloid Leukemia/ Flow cytometry / Cellular Biology / Drug resistance.

Secondary: Next Generation Sequencing, Gene Regulation, Lymphoma, Multiple Myeloma, Transcriptomics.

Memberships

Other Relevant Information